Cosmos Health (NASDAQ:COSM) Posts Quarterly Earnings Results, Misses Expectations By $0.11 EPS

Cosmos Health (NASDAQ:COSM) released its quarterly earnings data on Monday. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.11), FiscalAI reports. Cosmos Health had a negative return on equity of 52.85% and a negative net margin of 30.41%.The company had revenue of $18.99 million for the quarter, compared to analysts’ expectations of $19.42 million.

Cosmos Health Price Performance

Shares of NASDAQ COSM opened at $0.21 on Wednesday. The company has a current ratio of 1.08, a quick ratio of 0.92 and a debt-to-equity ratio of 0.31. The company’s 50-day moving average price is $0.22 and its 200 day moving average price is $0.30. Cosmos Health has a 52 week low of $0.16 and a 52 week high of $1.32. The stock has a market cap of $12.40 million, a price-to-earnings ratio of -0.32 and a beta of 4.80.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised Cosmos Health from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 30th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Cosmos Health has an average rating of “Sell”.

Insider Transactions at Cosmos Health

In other Cosmos Health news, CEO Grigorios Siokas acquired 766,284 shares of the company’s stock in a transaction dated Wednesday, July 29th. The stock was acquired at an average cost of $0.18 per share, with a total value of $137,931.12. Following the purchase, the chief executive officer directly owned 14,248,092 shares in the company, valued at approximately $2,564,656.56. This trade represents a 5.68% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, CFO Georgios Terzis acquired 168,135 shares of the company’s stock in a transaction dated Tuesday, June 16th. The shares were acquired at an average cost of $0.25 per share, with a total value of $42,033.75. Following the completion of the purchase, the chief financial officer owned 2,235,398 shares in the company, valued at approximately $558,849.50. This represents a 8.13% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders have acquired 2,204,138 shares of company stock valued at $457,137. 26.15% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Cosmos Health

A number of large investors have recently bought and sold shares of the stock. Citadel Advisors LLC raised its holdings in shares of Cosmos Health by 133.1% in the third quarter. Citadel Advisors LLC now owns 225,507 shares of the company’s stock worth $250,000 after acquiring an additional 128,776 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Cosmos Health by 260.5% during the fourth quarter. Renaissance Technologies LLC now owns 334,575 shares of the company’s stock valued at $167,000 after acquiring an additional 241,775 shares during the last quarter. Finally, XTX Topco Ltd increased its position in Cosmos Health by 52.1% during the 4th quarter. XTX Topco Ltd now owns 99,610 shares of the company’s stock worth $50,000 after purchasing an additional 34,117 shares in the last quarter. Institutional investors and hedge funds own 12.61% of the company’s stock.

About Cosmos Health

Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors.